- Home
- SVRA vs CMRX Comparison
SVRA vs CMRX Comparison
Compare SVRA & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- CMRX
- Stock Information
- Founded
- SVRA N/A
- CMRX 2000
- Country
- SVRA United States
- CMRX United States
- Employees
- SVRA N/A
- CMRX N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- SVRA Health Care
- CMRX Health Care
- Exchange
- SVRA Nasdaq
- CMRX Nasdaq
- Market Cap
- SVRA 458.2M
- CMRX 394.1M
- IPO Year
- SVRA N/A
- CMRX 2013
- Fundamental
- Price
- SVRA $2.69
- CMRX $5.15
- Analyst Decision
- SVRA Buy
- CMRX Strong Buy
- Analyst Count
- SVRA 7
- CMRX 2
- Target Price
- SVRA $9.86
- CMRX $8.50
- AVG Volume (30 Days)
- SVRA 633.7K
- CMRX 1.7M
- Earning Date
- SVRA 03-06-2025
- CMRX 03-07-2025
- Dividend Yield
- SVRA N/A
- CMRX N/A
- EPS Growth
- SVRA N/A
- CMRX N/A
- EPS
- SVRA N/A
- CMRX N/A
- Revenue
- SVRA N/A
- CMRX $159,000.00
- Revenue This Year
- SVRA N/A
- CMRX N/A
- Revenue Next Year
- SVRA N/A
- CMRX $1,690.28
- P/E Ratio
- SVRA N/A
- CMRX N/A
- Revenue Growth
- SVRA N/A
- CMRX N/A
- 52 Week Low
- SVRA $2.59
- CMRX $0.75
- 52 Week High
- SVRA $5.70
- CMRX $5.53
- Technical
- Relative Strength Index (RSI)
- SVRA 40.81
- CMRX 76.25
- Support Level
- SVRA $2.65
- CMRX $3.94
- Resistance Level
- SVRA $2.91
- CMRX $5.53
- Average True Range (ATR)
- SVRA 0.11
- CMRX 0.30
- MACD
- SVRA 0.01
- CMRX 0.07
- Stochastic Oscillator
- SVRA 23.08
- CMRX 78.29
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.